167 related articles for article (PubMed ID: 33534029)
1. Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats.
Morishima Y; Shibutani T; Noguchi K; Ito Y; Honda Y
J Thromb Thrombolysis; 2021 Jul; 52(1):9-17. PubMed ID: 33534029
[TBL] [Abstract][Full Text] [Related]
2. Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents.
Honda Y; Kamisato C; Morishima Y
Eur J Pharmacol; 2016 Sep; 786():246-252. PubMed ID: 27288116
[TBL] [Abstract][Full Text] [Related]
3. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Honda Y; Kamisato C; Morishima Y
Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
[TBL] [Abstract][Full Text] [Related]
4. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
Morishima Y; Kamisato C; Honda Y
Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572
[TBL] [Abstract][Full Text] [Related]
5. A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice.
Morishima Y; Honda Y
J Thromb Thrombolysis; 2018 Jul; 46(1):95-101. PubMed ID: 29704172
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
Shirasaki Y; Morishima Y; Shibano T
Thromb Res; 2014 Apr; 133(4):622-8. PubMed ID: 23932349
[TBL] [Abstract][Full Text] [Related]
7. Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats.
Furugohri T; Fukuda T; Tsuji N; Kita A; Morishima Y; Shibano T
Eur J Pharmacol; 2012 Jul; 686(1-3):74-80. PubMed ID: 22546231
[TBL] [Abstract][Full Text] [Related]
8. Prevention of Stent Thrombosis in Rats by a Direct Oral Factor Xa Inhibitor Edoxaban.
Morishima Y; Honda Y; Kamisato C
Pharmacology; 2019; 103(1-2):17-22. PubMed ID: 30343300
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
[TBL] [Abstract][Full Text] [Related]
10. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
Hillarp A; Strandberg K; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Lindahl TL
Scand J Clin Lab Invest; 2018; 78(7-8):575-583. PubMed ID: 30278787
[TBL] [Abstract][Full Text] [Related]
11. Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.
Fukuda T; Tsuji N; Honda Y; Kamisato C; Morishima Y; Shibano T
Thromb Haemost; 2011 Dec; 106(6):1062-8. PubMed ID: 21946952
[TBL] [Abstract][Full Text] [Related]
12. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.
Douxfils J; Chatelain B; Chatelain C; Dogné JM; Mullier F
Thromb Haemost; 2016 Jan; 115(2):368-81. PubMed ID: 26510969
[TBL] [Abstract][Full Text] [Related]
13. Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists.
Honda Y; Morishima Y
Thromb Res; 2015 May; 135(5):958-62. PubMed ID: 25791908
[TBL] [Abstract][Full Text] [Related]
14. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
Morishima Y; Honda Y; Kamisato C; Tsuji N; Kita A; Edo N; Shibano T
Thromb Res; 2012 Sep; 130(3):514-9. PubMed ID: 22647432
[TBL] [Abstract][Full Text] [Related]
16. Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.
Wolzt M; Samama MM; Kapiotis S; Ogata K; Mendell J; Kunitada S
Thromb Haemost; 2011 Jun; 105(6):1080-90. PubMed ID: 21544313
[TBL] [Abstract][Full Text] [Related]
17. Edoxaban: a focused review of its clinical pharmacology.
Lip GY; Agnelli G
Eur Heart J; 2014 Jul; 35(28):1844-55. PubMed ID: 24810388
[TBL] [Abstract][Full Text] [Related]
18. Combined effect of a direct oral anticoagulant edoxaban and an inhibitor of activated thrombin-activatable fibrinolysis inhibitor on clot lysis.
Morishima Y; Kamisato C; Honda Y
J Thromb Thrombolysis; 2020 Jan; 49(1):94-99. PubMed ID: 31396790
[TBL] [Abstract][Full Text] [Related]
19. Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity.
Narita Y; Hamamura K; Kashiyama M; Utsumi S; Kakizoe Y; Kondo Y; Ishitsuka Y; Jono H; Irie T; Mukoyama M; Saito H; Kadowaki D; Hirata S; Kitamura K
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450643
[TBL] [Abstract][Full Text] [Related]
20. Edoxaban: a new oral direct factor xa inhibitor.
Camm AJ; Bounameaux H
Drugs; 2011 Aug; 71(12):1503-26. PubMed ID: 21861537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
